

Alpha-1 antitrypsin (α_1 -AT) plasma levels in lung, prostate and breast cancer patients

Zeyad J. EL-AKAWI¹, Fatin K. AL-HINDAWI², Nabil A. BASHIR³

1. Associate Professor, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
2. M.Sc, Clinical Biochemistry, Department of Laboratory Sciences, Faculty of Applied Medical Sciences/Jordan University of Science and Technology, Irbid 22110, Jordan.
3. Professor, Department of Biochemistry and Molecular Biology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan

Correspondence to: Zeyad El-Akawi, M.D., M.A., Ph.D.
Associate Professor, Department of Biochemistry and Molecular Biology,
Vice Dean, Faculty of Medicine/Jordan University of Science and Technology,
Irbid 22110, Jordan
PHONE: Office: +962 2 720-1000 Ext. 23837, 23783
Secretary: +962 2 720-1000 Ext. 23785, 23696
CELL PHONE: +962 079/5917878; FAX: +962 2 7201064
E-MAIL: zakawi@just.edu.jo

Submitted: 2007-10-21 Accepted: 2008-05-11 Published online: 2008-08-30

Key words: **alpha-1 antitrypsin; cancer; lung; prostate; breast**

Neuroendocrinol Lett 2008;29(4):482-484 PMID: 18766166 NEL290408A01 © 2008 Neuroendocrinology Letters • www.nel.edu

Abstract

BACKGROUND AND OBJECTIVES: Alpha-1 antitrypsin (α_1 -AT) is one of the most important extra-cellular serine protease inhibitors. Elevation of α_1 -AT serum levels have been observed in the course of a large number of malignant diseases. In this study, using Radial Immunodiffusion Method, we studied the serum levels of α_1 -AT in lung, prostate and breast cancer patients.

RESULTS: Lung and prostate cancer patients have shown a significant elevation in α_1 -AT serum levels compared with those of healthy controls (*P*-value = 0,0001, 0,003 respectively). On the other hand, breast cancer patients did not show a significant change in these levels. Serum levels of α_1 -AT were 261.7 ± 107.26 , 222.7 ± 87.30 and 183.8 ± 45.05 mg/dl of lung, prostate and breast cancer patients, respectively, while those of healthy controls were 163.9 ± 23.2 mg/dl in males and 186.13 ± 39.81 mg/dl in females.

CONCLUSION: These data demonstrated that α_1 -AT plasma levels might be an alarming factor to be considered in the diagnosis as well as in the follow up of cancer cases.

INTRODUCTION:

Human alpha 1-antitrypsin (α_1 -AT) is one of the major components of the plasma proteins. It inhibits serine proteases and acts as an acute phase glycoprotein [1]. α_1 -AT is the principle inhibitor of leukocyte elastase, trypsin, chymotrypsin, cathepsin G, plasmin, thrombin, tissue kallikrein, factor Xa, plasminogen and proteinase III [2,3,4]. α_1 -AT

concentrations are known to rise in the blood during the course of malignant diseases such as: hepatocellular carcinoma (HCC) [5,6], multiple myeloma and lymphoma [7,8], pancreatic carcinoma [9], prostatic carcinoma [10,11], primary carcinoma of the lung [12,13,14,15], primary liver cancer (PLC)[16], bowel cancer [17], cervical carcinoma [18,19], gastric cancer [20], laryngeal carcinoma [21], breast cancer at the time of recurrence [22],

and colorectal carcinoma [23]. This increase in α_1 -AT levels was also observed in chronic diseases such as, liver cirrhosis and hepatitis [6,24], duodenal ulcer disease [25], active retinal vasculitis [26], and crohns disease [27]. In addition a comparative analysis of tumors and normal tissues of origin showed a good correlation between reduced local α_1 -AT expression and more aggressive tumor growth [28]. In this study we tested the α_1 -AT serum levels in Jordanian lung, prostate and breast cancer patients and compared with those of healthy controls.

MATERIALS AND METHODS:

Blood samples were obtained from eighty-three patients with three different types of cancer, thirty-three breast cancer, twenty-five male lung cancer, and twenty-five prostate cancer at Radiotherapy and Chemotherapy Treatment Department in Al-bashir Hospital. Blood samples of sixty-seven non-smokers healthy adult controls (forty-three females and twenty-four males) were obtained from blood donors at National Blood Bank in Al-bashir Hospital and Princess Basma Teaching Hospital. Venous blood was drawn into plain tubes. All serum samples were evaluated for α_1 -AT concentration within 2hrs after blood samples collection using Radial Immunodiffusion Technique (RID), following the company instructions. Duplicate measurements were carried out for each sample and the average result was used. The accuracy of the procedure was determined with control sera containing predetermined concentration of α_1 -AT.

Statistical analysis was performed using t-test and ANOVA test. Differences between mean levels were considered significant if obtained *P-value* was less than 0.05.

RESULTS:

The mean plasma levels of α_1 -AT in patients with prostate and lung cancer compared with those of healthy male controls have shown significant differences. As shown in Table-1, the mean plasma α_1 -AT levels in prostate and lung cancer patients were 222.7 ± 87.3 mg/dl and 264.7 ± 108.4 mg/dl respectively, while in male controls the mean level was 163.9 ± 23.2 mg/dl, *P-value* = 0.003 and 0.0001, correspondingly. Breast cancer patients have shown mean serum level of 183.8 ± 45.05 mg/dl, this value was very close to that in healthy female controls 186.13 ± 39.8 mg/dl (*P-value* = 0.815), as shown in Table-2. Among the three types of cancer, lung cancer patients have shown the highest α_1 -AT serum levels followed by prostate cancer.

DISCUSSION:

Proteolytic enzymes play an important role in cancer pathology, but the role of the body's natural inhibitors of these enzymes in this process is not very well stud-

ied. α_1 -AT is the major serine protease inhibitor in plasma. Researchers have been trying to find a correlation between α_1 -AT and the process of neoplasia that may help in the diagnosis and the follow up of the cancer patient. Various studies were performed on the behavior of α_1 -AT in different types of cancer such as; lung, breast, liver, prostate, pancreas, cervix, and colorectal cancer. Most of these studies were reported the elevation of α_1 -AT plasma levels in cancer patients. [5,6,9,10,11,12,13,15,16,17,18,19,22,23]. In this work we studied a group of eighty-four patients with three different types of cancer, lung, prostate and breast. Each patient had the α_1 -AT serum level measured by radial immunodiffusion. As results indicated, nineteen out of twenty-five lung cancer patients 76%, have shown a significantly higher mean levels of serum α_1 -AT than that in male controls. Our data were similar to what was reported in earlier studies [29,12,13,14,15]. Daddi *et al.*, demonstrated that in more than 90% of lung cancer patients the serum level of α_1 -AT was significantly higher than that of controls [13]. The lower percentage of lung cancer patients with elevated α_1 -AT levels in our study compared with those found by Daddie *et al.*, might due to the fact that patients in this study were randomly selected, independent on being treated or untreated. Patients with prostate cancer, as well, have shown a significant rise in the concentration of α_1 -AT. Thirteen out of twenty-five (52%) had a higher α_1 -AT concentration compared with controls. This finding is in accordance with that observed by Zietek *et. al.*, 1996 and Milford *et. al.*, 1977. They found that α_1 -AT serum levels and activity were increased with the development of prostate cancer [10,11]. Kuvibidila and Rayford also demonstrated a significant elevation in serum α_1 -AT in prostate cancer patients and their direct correlation with prostate-specific antigen serum levels [30]. In the results section the high standard deviation numbers of α_1 -AT serum levels in lung and prostate cancer patients due to wide range concentrations of this protein in these patients. This wide range serum levels among different cancer patients might be explained by the differences in the stage and the grade of the disease as well as the type and duration of treatment they were receiving. This explanation is supported by Daddi *et. al.*, demonstrated that the level of α_1 -AT in lung cancer patients vary during the course of the disease [13]. Also, Milford *et. al.*, have shown that there were differences in α_1 -AT serum level between prostate cancer patients with different stages of the disease [11].

Breast cancer patients who were studied in this work did not show an elevation in their α_1 -AT serum concentration. These findings concerning breast cancer were different from what was reported in previous studies. Increased α_1 -AT blood level was shown to be associated with breast tumors [22,31,32]. Thompson *et. al.*, and Demidove *et. al.*, have observed a rise in the serum levels of breast cancer patients as compared with healthy individuals and this elevation was associated with

Table-1: α_1 -AT levels in lung and prostate cancer patients

Group	No. of individuals	α_1 -AT mean values mg/dl	SD
Lung cancer	25	264.7*	± 108.4
Prostate cancer	25	222.7**	± 87.3
Control (males)	24	163.9	± 23.2

*P-value = 0.0001; **P-value = 0.003

tumor advancement [31,32]. On the contrary, Doustjalali S.R *et al.*, showed that the expression of α_1 -AT in breast cancer patients was apparently lower than that of the controls [33].

In conclusion, our data demonstrated that elevated α_1 -AT plasma levels might be an alarming factor to be considered in the diagnosis as well as in the follow up of lung and prostate cancer but it is a poor marker for breast cancer.

REFERENCES:

- Carrell WR, Jeppson J, Laurell C, Brennan OS, Owen CM, Vaughan L, et al. Structure and variation of human alpha-1 antitrypsin. *Nature* 1982; **298**: 329–33.
- Crystal GR, Brantly LM, Hubbard CR, Curried TD, States JD, Holmes DM. The alpha-1 antitrypsin gene and its mutations. *Chest* 1989; **95**(1): 196–208.
- Coakley RJ, Taggart C, O'Neill S, McElvaney NG. Alpha-1 antitrypsin deficiency: biological answers to clinical questions. *Am. J. Med. Sci.* 2001; **321**(1): 33–41.
- Huber R, Carrell RW. Implications of the three-dimensional structure of alpha-1 antitrypsin for structure and function of serpins. *Biochemistry* 1989; **28**(23): 8951–66.
- Sparos L, Tountas Y, Chapuis-Cellier C, Theodoropoulos G, Trichopoulos D. Alpha-1 antitrypsin levels and phenotypes and hepatitis B Serology in liver cancer. *Br. J. Cancer* 1984; **49**: 567–70.
- Debrowska M, Mantur M, Panasiuk A, Prokopowicz J. Does the concentration of alpha-1 proteinase inhibitor reflect the transformation of liver cirrhosis to liver carcinoma? *Neoplasma* 1997; **44**(5): 305–7.
- Ananhtakrishnan R, Biegler B, Dennis PM. Alpha-1 antitrypsin phenotypes in paraproteinemias, *The Lancet* 1979; **10**: 561–2.
- Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Tienhaara A, Laakso M, et al. for the Finnish Leukemia Group, Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. *Blood* 1995; **85**(3): 765–71.
- Tountas Y, Sparos L, Theodoropoulos C, Trichopoulos D. Alpha-1 antitrypsin and cancer of the pancreas. *Digestion* 1985; **31**(1): 37–40.
- Zietek Z, Iwan-Zietek I, Kotschy M, Tyloch F, Activity of alpha-1 antitrypsin in blood of patients with prostatic tumor. *Pol. Tyg. Lek* 1996; **51**(6–9): 89–90.
- Ward AM, Cooper EH, Houghton AL. Acute-phase reactant proteins in prostatic cancer. *British Journal of Urology* 1977; **49**: 411–18.
- Bata J, Colobert L, Biron A, Brune J, Study of various serum proteins in lung cancer. *Immunoglobulins A, G, M, haptoglobin, alpha-1 antitrypsin, alpha-2 macroglobin.* *Annales de Biologie Clinique* 1977; **35**(4): 297–303.
- Daddi G, Mancini PA, Parola D, Contini A. Alpha-1 antitrypsin increase in lung cancer. *Bollettino dell'Istituto Sieroterapico milanese* 1976; **55**(6): 510–2.
- Apicella C, Carniato A, Ippoliti F, Romano V, Tomai A, Ferrari S. Relations between serum alpha-1 antitrypsin level and neoplasms. *Archivio Per le Scienze Mediche* 1976; **133**(2): 103–8.
- Harris CC, Cohen MH, Conner R, Primack A, Saccomanno G, Talamo RC. Serum alpha-1 antitrypsin in patients with lung

Table-2: α_1 -AT levels in breast cancer patients and female controls.

Group	No. of individuals	α_1 -AT mean values mg/dl	SD
Breast cancer	33	183.8	± 45.05
Control (females)	43	186.13	± 39.81

P-value = 0.815

- cancer or abnormal sputum cytology. *Cancer* 1976; **38**(4): 1655–7.
- Hirmatsu S, Kojima J, Okada TT, Ohmori IK. The serum protein profile in chronic hepatitis, cirrhosis and liver cancer. *Acta hepato-gastroenterologica* 1976; **23**(3): 177–82.
 - Ward AM, Cooper EH, Turner R, Anderson JA, Neville AM. Acute-phase reactant profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes, *British Journal of Cancer* 1977; **35**(2): 170–8.
 - Latner AL, Turner GA, Lamin MM. Plasma alpha-1 antitrypsin levels in early and late carcinoma of the cervix. *Oncology* 1976; **33**(1): 12–4.
 - Patenoster D, Cartei G, Campagnutta E, Maggino T, Valente S, Ongaro G. Acute reactive stage proteins in gynaecologic cancers. *Eur. J. Gynaecol. Oncol.* 1980; **1**(2): 94–8.
 - Dumitrascu D, Radu D, Stanciul L, Ionita A, Petcovici M. Alpha-1 antitrypsin, alpha-2-macroglobulin and reactive protein C in gastric cancer. *Rev. Med. Interna. Neurol. Psihiatr. Neurochir. Dermatovenerol. Med. Interna.* 1989; **41**(1): 57–61.
 - Krecicki T, Leluk M. Acute phase reactant proteins: an aid to monitoring surgical treatment of laryngeal carcinoma. *J. Laryngol. Otol.* 1992; **106**(7): 613–5.
 - Mattison P, Cove DH, Walsh L, Howell A, Mc Conkey B, Morrison JM. Serum proteins as tumor markers for breast cancer. *Br. J. Cancer* 1981; **43**: 542–5.
 - Amiguet JA, Jimenez J, Monreal JI, Hernandez MJ, Lopez-Vivanco G, Vidan JR, et al. Serum proteolytic activities and antiproteases in human colorectal carcinoma. *J. Physiol. Biochem.* 1998; **54**(1): 9–13.
 - Chio LF, Oon C. Changes in serum alpha-1 antitrypsin, alpha-1 acid glycoprotein and beta-2 glycoprotein 1 in patients with malignant hepatocellular carcinoma. *Cancer* 1979; **43**: 596–604.
 - Beimond I, Goedhard JG, Klasen EC, Vanden Boomgaard DM, Kreuning J, Pe'a AS, et al. Alpha-1 antitrypsin phenotypes and serum concentrations in duodenal ulcer patients in the Netherlands. *Digestion* 1988; **39**(1): 20–5.
 - Wakefield D, Easter J, Breit SN, Clark P, Penny R. Alpha-1 antitrypsin serum levels and phenotypes in patients with retinal vasculitis. *Br. J. Ophthalmol.* 1985; **69**(7): 497–9.
 - Klasen EC, Beimond I, Weterman IT. Alpha-1 antitrypsin levels and phenotypes in Crohn's disease in the Netherlands. *Gut* 1980; **21**(10): 840–2.
 - Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, et al. Alpha-1-antitrypsin inhibits angiogenesis and tumor growth. *Int. J. Cancer* 2004; **112**(6): 1042–8.
 - Micksche M, Kokron O. Serum levels of alpha-1 antitrypsin and alpha-2 macroglobulin in lung cancer. *Das osterreichische Kneipp-Magazin* 1977; **3**(5–6): 116–9.
 - Kuvibidila S, Rayford W. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. *J. Lab. Clin. Med.* 2006; **147** (4): 174–81.
 - Demidove VP, Iakubovskaia RI, Karmakova TA, Avdeev GI, Komissarov AB, Sorokin EE, et al. Alpha-1 proteinase inhibitor in breast cancer. *Vopr. Onkol.* 1990; **36**(1): 23–9.
 - Thompson DK, Haddow JE, Smith DE, Ritchie RF. Elevated serum acute phase protein levels as predictors of disseminated breast. *Cancer* 1983; **51**(11): 2100–4.
 - Doustjalali SR, Yusof R, Yib CH, Looi LM, Pillay B, Hashim OH. Abberent expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. *Electrophoresis* 2004; **25**(14): 2392–401.